News

At the 2025 AAD Annual Meeting, Gooderham shared data on the negligible systemic exposure of delgocitinib cream for chronic hand eczema.

In the first Derm Dispatch episode, Renata Block, MMS, PA-C, and Peter Lio, MD, discuss integrative approaches to managing eczema, including the use of holistic treatments.

This month and all year round, we recognize the strides and contributions of female leaders in dermatology.

The integration of pharmacotherapy in obesity treatment provides a structured approach to weight loss for patients who struggle with traditional methods.

Exclusive Q1 Report: A comprehensive look at the latest FDA approvals and pipeline developments in dermatology from the first quarter of 2025.

PASI and DLQI scores are closely linked, but stigma and residual effects may still impact patient QoL.

Explore the top headlines of the week including insights on clinical trials, CBD products, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about CBD products in dermatology, Journey Medical's launch of Emrosi for rosacea, the psychological impact of melanoma, and more.

This week, we feature top articles from our sister publications on clinical trials, FDA updates, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Learn more about the in-depth topics covered in the March 2025 print issue of Dermatology Times.

Patients with CHE saw higher treatment success and a favorable safety profile with delgocitinib 20-30 mg/g.

Explore the top headlines of the week including insights on recalls, expert pearls, and more.

Two-sample Mendelian randomization analysis explored lifestyle factors such as sleep, smoking, alcohol consumption, and sedentary behavior.

With an increasing demand for laser procedures, AI-based skin assessments may help ensure safer and more effective treatments.

The therapy, which combines clindamycin phosphate, adapalene, and benzoyl peroxide, was effective for Hispanic patients with moderate to severe lesions.

Dermatology Times is looking back on the top stories in dermatology from the month of March.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Xyngari showed promise as the first once-weekly topical acne treatment, achieving strong phase 3 results with significant efficacy and safety.

The cream contains barrier-repairing ingredients that may enhance self-healing and hydration in affected skin.

In a prospective study, patients with scalp seborrheic dermatitis saw positive results in efficacy, safety, and quality of life when using the AgNP product.

Treatment with tildrakizumab was still safe and effective after 1 year with notable improvements in patients’ quality of life.

Nearly half of patients with melanoma experience significant distress, affecting treatment adherence and quality of life.

Dermatology Times is recapping our exclusive expert interviews from the month of March.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Use of the product showed positive changes in the skin’s hydration, lipid content, transepidermal water loss, and erythema.

A study shows active educational interventions improve melanoma detection rates and rule application, with lasting effects over time.

Researchers behind a recent review shared expert insights, treatment guidelines, and differential diagnosis techniques for pediatric rosacea.

When compared to a non-active product, the formula improved texture, reduced erythema, and strengthened the skin barrier.